National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 6) (No. PB 49 of 2014) (Cth)

PB 49 of 2014

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 6)

National Health Act 1953

___________________________________________________________________________

I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Medical Research, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 27 June 2014

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Principal Pharmacy Advisor  

Pharmaceutical Benefits Division

Department of Health ___________________________________________________________________

1              Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.6).

(2)This Instrument may also be cited as PB 49 of 2014.

2             Commencement

This Instrument commences on 1 July 2014.

3              Amendments to PB 79 of 2011

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1                   Amendments

1. Section 3, Definition for diluent fee

omit:                    $4.91   substitute:      $5.00

1. Section 3, Definition for dispensing fee

omit:                    $6.63   substitute:      $6.76

1. Section 3, Definition for distribution fee

omit:                    $24.79   substitute:      $25.26

1. Section 3 Definition for preparation fee

omit:                    $101.33   substitute:      $102.12

1. Schedule 1 Part 1 entry for Docetaxel in the form ‘Solution concentrate for I.V. infusion 140 mg in 7 mL’ and brand ‘Oncotaxel 140’:

omit from the column headed “Responsible Person”: TA               substitute: GN

1. Schedule 1 Part 1 entry for Docetaxel in the form ‘Solution concentrate for I.V. infusion 20 mg in 1 mL’ with manner of administration Injection:

omit :

Oncotaxel 20 TA MP C3888 C3892 C3916 C3956 C4078 C4140 C4160 C4239 D

1. Schedule 1 Part 1 entry for Docetaxel in the form ‘Solution concentrate for I.V. infusion 80 mg in 4 mL’ and brand ‘Oncotaxel 80’:

omit from the column headed “Responsible Person”: TA               substitute: GN

1. Schedule 1 Part 1 entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL’ and brand ‘Epirubicin Actavis 10’:

omit from the column headed “Responsible Person”: TA               substitute: UA

1. Schedule 1 Part 1 entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL’ and brand ‘Epirubicin Actavis 20’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[10]  Schedule 1 Part 1 entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL’ and brand ‘Epirubicin Actavis 200’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[11]  Schedule 1 Part 1 entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ and brand ‘Epirubicin Actavis 50’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[12]  Schedule 1 Part 1 entry for Fludarabine in the form ‘Powder for I.V. injection containing fludarabine phosphate 50 mg’ and brand ‘Fludarabine Actavis’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[13]  Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL’ and brand ‘Irinotecan Actavis’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[14]  Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with manner of administration Injection:

omit :

Irinotecan Actavis TA MP D

[15]  Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL’ and brand ‘Irinotecan Actavis 500’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[16]  Schedule 1 Part 1 entry for Oxaliplatin in each of the forms: ‘Powder for I.V. infusion 100 mg’; and ‘Powder for I.V. infusion 50 mg’ and brand ‘Oxaliplatin Actavis’:

omit from the column headed “Responsible Person”: TA               substitute: UA

[17]  Schedule 1 Part 1, entry for Paclitaxel in each of the forms: ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’;  ‘Solution concentrate for I.V. infusion 150 mg in 25 mL’; ‘Solution concentrate for I.V. infusion 30 mg in 5 mL’; and ‘Solution concentrate for I.V. infusion 300 mg in 50 mL’ and brand ‘Paclitaxel Actavis’:

omit from the column headed “Responsible Person: TA                 substitute: UA

[18]  Schedule 3, after the entry for the code SZ:

omit:

TA Actavis Australia Pty Ltd 43    122 896 468

[19]  Schedule 3, after the entry for the code TX:

insert:

UA Actavis Pty Ltd  17  003 854 626